AI & Bioscience Forum 7/27/2019
Updated: Jul 30, 2019
Orgainizers: CBA and Monte Jade West Date: 7/27/2019 Time: 1:30PM - 5:30PM Location: Jones Day Silicon Valley Office, 1755 Embarcadero Road, Palo Alto, CA, 94303 Registration: here. Online registration is required. Fees: Free for CBA members and Monte Jade members; $10 for non members and on-site registration.
Speakers: -Stephanie M. Brooker, Associate Attorney, Jones Day Title: Biotech Meets AI – Potential IP Protection Strategies -Samuel Chen, CEO AiXMed Title: AI Trend in Healthcare -Possu Huang, Assistant Professor of Stanford University -Andrew M. Radin, Co-Founder twoXAR Title: Accelerating Drug Discovery with Technology -Sue Xu, Managing Partner, Amino Capital Title: AI in Healthcare – How to Cut Through the Hype
-Stephanie M. Brooker, Associate Attorney, Jones Day
Stephanie Brooker is a patent lawyer who handles prosecution of U.S. and foreign patent applications. Her practice spans technical areas including artificial intelligence, blockchain, semiconductor manufacturing and devices, data and digital signal processing, file and database management software, graphical user interfaces, software architectures, medical devices and patient monitoring systems, digital health, fitness equipment, on-board diagnostic devices, and power control systems. Stephanie has experience in freedom to operate and invalidity analyses as well as trade secret litigation. Stephanie supports veterans of the U.S. Armed Forces by being actively involved in pro bono initiatives. Prior to law school, Stephanie spent five years working in industry performing software testing and systems integration. She began her career in defense contracting with the Navy working with combat systems weapon and sensor software development. She also worked in the telematics industry, designing and testing telematics software.
-Samuel Chen, CEO AiXMed
With 25+ years’ experience in software development, Mr. Samuel Chen is the president and CEO for AIxMed, a Silicon Valley startup company founded June 2018 focusing on applying machine learning in medicine. Currently AIxMed is collaborating with hospitals, university, research institute, and medical device companies.
Mr. Chen started his early software career as a senior engineer at National Semiconductor, and SunSoft Java development team. In 1997, Chen was recruited to Trend Micro, a global Internet security powerhouse started from Taiwan. As the VP of Software Development, Mr. Chen led a global engineering team consisted of 500+ staffs distributed among 6 countries. During his 10-year tenure, Mr. Chen established Trend Micro’s first software development lifecycle and process, and the company also grew into Taiwan’s # 1 software company and ranked among top 3 information security companies in the world.
With the interest of integrating software capability into Taiwan’s electronic hardware industry, Chen joined ASUSTek in 2008 and served as VP/Chief Engineering Staff to CEO, in charge of ASUSTek corporate software strategy. In 2011, Chen was invited by Compal vice chairman to join Compal Electronics forming a 500-member corporate software organization in Compal. Chen was in charge of software development for Android and IoT products. In 2016, Chen turned his interest into AI and machine learning, and became the founding VP of Compal AI Lab. At Compal, Chen later led a small team to win a silver medal in Kaggle Data Science Bowl 2018.
Chen learned computer programming as a hobby since high school, and he won 2 national championships in Software Design Contest administrated by Ministry of Education, Taiwan, in 1983 (high school) and 1986 (Division 1, college and above.)
Chen graduated from National Chiao-Tung University with a bachelor’s degree in computer engineering, and holds a master’s degree in computer science from University of Southern California.
-Possu Huang, Assistant Professor of Stanford University
-Assistant Professor, Bioengineering
-Faculty Fellow, Stanford ChEM-H
-Senior Fellow, University of Washington
-Ph.D., California Institute of Technology, Biochemistry and Molecular Biophysics
-B.A., UC Berkeley, MCB - Biochemistry
-Andrew M. Radin, Co-Founder twoXAR
Andrew M. Radin formerly worked as an investor in venture and private equity funds at Macquarie Bank and has designed, built, and managed several small organizations. Andrew co-founded a mobile platform startup while at MIT. As a Co-Founder, Andrew acts as an ambassador of twoXAR to build relationships with biopharmaceutical partners and investors. Andrew holds a Master in Business Administration degree from MIT Sloan, a Bachelor of Science degree in biochemistry and cell biology from UCSD, and a Bachelor of Arts degree in economics from UCSD.
-Sue Xu, Managing Partner, Amino Capital
Dr. Sue Xu is a Managing Partner at Amino Capital, and her focus areas of investment include data-driven solutions and blockchain web3.0 protocols. She was interim CEO of CandyHouse, Databeyond and CyteSi. Since 2012, she has involved with more than 150 investments, including Assemblage (acquired by Cisco), Orbeus (acquired by Amazon), Ozlo (acquired by Facebook), GrokStyle(acquired by Facebook), Woomoo (acquired by Priceline), Contastic (acquired by Sugar CRM), Mobike (acquired by Meituan/Tencent), Evertoon (Acquired by Niantic | PokemonGo), Yiqixie (Acquired by Kuaishou/Tencent), Voyage, AIFI.io, Vicarious, Paperspace, Skycatch, Skuchain, Webflow and Grail.
We are also early backers of next generation blockchain protocol since 2014, and led the seed and A round of String Labs, which incubated one the most anticipated public chain, DFINITY. We participated in investment of OASIS, DFINITY, Kadena, TrustToken, NuCypher, and OmiseGo, which later became known as the first blockchain unicorn in 2017.